HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

George Fountzilas(Hellenic Cooperative Oncology Group), P. Arapantoni(Metaxa Hospital)
Journal of Translational Medicine
January 12, 2012
Cited by 100


Related Papers